All Articles

The introduction of BRAF- and MEK-targeted therapies and immune checkpoint inhibitors has significantly improved outcomes in patients with metastatic melanoma. However, many patients have drug resistance—acquired or primary—which results in death from underlying disease. Read More ›

In the phase 2 STORM Part 1 clinical trial, 21% of patients with refractory multiple myeloma had a partial or better response to oral selinexor (Xpovio) plus dexamethasone. Those findings were the basis for the pivotal phase 2 STORM Part 2 study. Read More ›

The investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy known as JNJ-4528 induced responses in 100% of 29 evaluable patients with heavily pretreated relapsed or refractory multiple myeloma, according to the results of the phase 1b/2 CARTITUDE-1 clinical trial reported at ASH 2019. Read More ›

The investigational dual-targeted BM38 chimeric antigen receptor (CAR) T-cell therapy achieved an objective response in more than 90% of patients with relapsed or refractory multiple myeloma who had received ≥3 previous therapies and whose disease had spread outside of the bone marrow. Furthermore, the therapy cleared extramedullary lesions in almost all patients with these lesions, according to results presented at ASH 2019. Read More ›

A new CD45-targeting antibody radiation-conjugate, iodine-131 (I-131) apamistamab, may be a less toxic alternative to today’s standard practice of chemotherapy-based lymphodepletion regimens before initiation of adoptive cell therapy, according to results presented at ASH 2019. Read More ›

Mosunetuzumab is an investigational bispecific T-cell engager (BiTE) agent dually targeting 2 proteins on the surface of lymphoma cells—CD3 (on the surface of T-cells) and CD20 (on the surface of B-cells). Read More ›

Pivotal phase 3 data demonstrated treatment with luspatercept resulted in statistically significant increased red blood cell transfusion independence compared with placebo. Read More ›

Patients and healthcare providers should be aware of the toxicities that may occur with the use of PARP inhibitors so that they can manage them appropriately. Read More ›

Although federal reform efforts are likely to stall in the Senate, legislation prohibiting gag clauses, claw backs, and price spreading are being passed at the state level. Read More ›

The use of combination therapies in the first- and second-line settings for advanced ovarian cancer has the potential to improve patient outcomes. Read More ›